Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Fabry Disease Treatment Market
Fabry Disease Treatment Market Analysis
- Report ID: GMI4237
- Published Date: Sep 2022
- Report Format: PDF
Fabry Disease Treatment Market Analysis
Based on treatment type, the Fabry disease treatment market is segregated into ERT (enzyme replacement therapy) and chaperone therapy. The enzyme replacement therapy segment is projected to record a revenue of over USD 2.6 billion by 2030, considering the prominent role of this therapy in target disease treatment. ERT is designed to help identify the underlying causes of the disease and assist in the breakdown of fatty molecules. Replagal enzyme replacement therapy, for example, was designed to replace the human alpha-galactosidase A, which is a common deficiency observed in Fabry disease patients. Strong application scope and development of innovative treatments will thus stimulate segmental expansion over the estimated timeframe.
North America Fabry disease treatment market is expected to register a revenue of more than USD 1 billion by 2030. This can be credited to the novel product launch initiatives by industry players and the growing disease prevalence. Based on the population estimates of the Census Bureau, over 11,000 people are diagnosed with Fabry disease in the United States. In the region, ERT and chaperone treatment have also become viable options for the management of Fabry disease-induced complications, further influencing regional industry dynamics.
Frequently Asked Questions (FAQ) :
Fabry Disease Treatment Market Scope
